KahnJA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med, 2009; 361:271–278.
3.
StanleyMA. Genital human papillomavirus infections: Current and prospective therapies. J Gen Virol, 2012; 93:681–691.
4.
MendozaN, HernandezPO, TyringSK. HPV vaccine update: New indications and controversies. Skin Ther Lett, 2011; 16:1–3.
5.
WheelerCM, KjaerSK, SigurdssonKet al.The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis, 2009; 199:936–944.
6.
WinerRL, HughesJP, FengQet al.Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med, 2006; 354:2645–2654.
7.
PoppeWA, SimonPH, De RidderMR. Why consider human papillomavirus vaccination in older women?Gynecol Obstet Invest, 2010; 70:237–243.
8.
GrantLA, DunneEF, ChessonH, MarkowitzLE. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine, 2011; 29:2365–2370.
9.
FDA licensure of bivalent human papillomavirus vaccine (HPV2 Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization practices(ACIP)MMWR, 2010; 59:626–629.
10.
Recommended adult immunization schedule, United States 2012. www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a9.htm. 2012 June 7.
MunozN, ManalastasRJr, PitisuttithumPet al.Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: A randomised, double-blind trial. Lancet, 2009; 373:1949–1957.
